AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Fibroblast growth factor 23

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9GZV9

UPID:

FGF23_HUMAN

Alternative names:

Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

Alternative UPACC:

Q9GZV9; Q4V758

Background:

Fibroblast growth factor 23 (FGF23), also known as Phosphatonin and Tumor-derived hypophosphatemia-inducing factor, plays a pivotal role in phosphate homeostasis. It inhibits renal tubular phosphate transport, up-regulates EGR1 expression, and acts on the parathyroid to decrease PTH secretion. FGF23 is a key regulator of vitamin-D metabolism and negatively regulates osteoblast differentiation.

Therapeutic significance:

FGF23 is implicated in Hypophosphatemic rickets, autosomal dominant, characterized by renal phosphate wasting, and Tumoral calcinosis, hyperphosphatemic, familial, 2, marked by hyperphosphatemia and calcium deposits. Understanding the role of FGF23 could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.